Wearable cardioverter-defibrillator (life-vest): A feasible bridging treatment in adult congenital heart disease

Sarubbi, Berardo; Palma, Michela; Merola, Assunta; Fusco, Flavia; Correra, Anna; Colonna, D; Romeo, Emanuele; Grimaldi, N; Ciriello, Giovanni Domenico; Scognamiglio, Giancarlo; Russo, Maria Giovanna

doi:10.1016/j.ipej.2022.06.005

Cited by 3 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we may argue that the WCD is not beneficial for all patient groups with inherited and congenital heart disease. Even though there still is a lack of data for the use of WCD in these patients, in the published studies there are often no shocks or a low shock rate, similar to our study ( 13 , 14 , 16 , 17 ). Most appropriate shocks that are documented occurred in patients with inherited heart disease.…”

Section: Discussionsupporting

confidence: 83%

“…Our compliance rate can be compared to previously published studies, with Spar et al ( 16 ) reporting a median wear time of 20.6 h per day, Sarubbi et al ( 13 ) a wear time of 21.2 ± h/d, Rao at al. ( 14 ).…”

Section: Discussionmentioning

confidence: 66%

“…This shock rate of 0% was previously described in other studies about inherited and congenital heart diseases. E.g., Sarubbi et al described eight patients with congenital heart disease, also without WCD shocks ( 13 ).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

No beneficial use of the wearable cardioverter defibrillator among patients suffering from inherited and congenital heart disease: data from a European multicenter registry

Koepsel,

Dreher,

Blockhaus

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundData on the use of the wearable cardioverter defibrillator in patients suffering from inherited and congenital heart disease are limited. Consequently, evidence for guideline recommendations in this patient population is lacking.MethodsIn total 1,675 patients were included in a multicenter registry of eight European centers. In the present cohort, we included 18 patients suffering from congenital and inherited heart disease.ResultsNine patients (50%) were male with a mean age of 41.3 ± 16.4 years. Four patients suffered from hypertrophic cardiomyopathy (HCM), four patients suffered from non-compaction cardiomyopathy (NCCM), two patients were diagnosed with arrhythmogenic right ventricular cardiomyopathy (ARVC) and one patient suffered from muscular dystrophy of the limb-girdle type with cardiac involvement, secondary cardiomyopathy. Three patients presented with Brugada syndrome (BrS). One patient suffered from long-QT syndrome type 1 (LQTS1). Furthermore, two patients had congenital heart defects and one patient suffered from cardiac sarcoidosis (CS). There were no appropriate/inappropriate shocks with the WCD in this cohort. One patient had recurrent self-limiting sustained ventricular tachycardia during the wear time, but actively inhibited a shock and was hospitalized. The compliance rate in this cohort was 77.8% with a mean wear time of 45.3 ± 26.9 days with a mean follow-up time of 570 ± 734 days. 55.6% (10/18) of the patients received an ICD after WCD wear time.ConclusionsThis retrospective study of patients with inherited and congenital heart disease shows that WCD use is not beneficial in the majority of patients with inherited and congenital heart disease.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 66%

See 1 more Smart Citation

No beneficial use of the wearable cardioverter defibrillator among patients suffering from inherited and congenital heart disease: data from a European multicenter registry

Koepsel,

Dreher,

Blockhaus

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Therefore, we decided to remove the device and implant a new S‐ICD after 3 months. A wearable cardioverter defibrillator was applied in the meantime as bridge to reimplantation 2 . Inflammatory signs completely resolved after device extraction, and the patient remained asymptomatic during follow‐up.…”

Section: Case Presentationmentioning

confidence: 99%

Contact allergy to subcutaneous implantable cardioverter defibrillator in a child with Brugada syndrome

Ciriello,

Colonna,

Correra

et al. 2024

Pacing Clinical Electrophis

Self Cite

View full text Add to dashboard Cite

Allergic reactions to components of cardiac implantable electronic devices are rare and often go undiagnosed, which can lead to a misdiagnosis of device infection. Contact allergy to subcutaneous implantable cardioverter defibrillator (S‐ICD) is extremely rare. In this report, we present a case of cobalt‐related contact allergy in a pediatric patient with Brugada syndrome who underwent S‐ICD implantation.

show abstract

“…However, studies assessing the utility of the WCD in the adult CHD population are relatively lacking. Sarubbi and colleagues, in this issue of IPEJ present a single center experience of using the WCD in adults with complex CHD [ 4 ]. They report the results of WCD use in eight consecutive patients over an average duration of 4 months.…”

mentioning

confidence: 99%

Handling SCD risk in adult congenital heart disease: Should we InVEST in the WCD?

Narayanan¹

2022

Indian Pacing and Electrophysiology Journal

View full text Add to dashboard Cite

Wearable cardioverter-defibrillator (life-vest): A feasible bridging treatment in adult congenital heart disease

Cited by 3 publications

References 23 publications

No beneficial use of the wearable cardioverter defibrillator among patients suffering from inherited and congenital heart disease: data from a European multicenter registry

No beneficial use of the wearable cardioverter defibrillator among patients suffering from inherited and congenital heart disease: data from a European multicenter registry

Contact allergy to subcutaneous implantable cardioverter defibrillator in a child with Brugada syndrome

Handling SCD risk in adult congenital heart disease: Should we InVEST in the WCD?

Contact Info

Product

Resources

About